|
Intercept
|
10.4 (10.2, 10.5)
|
<0.001
|
|
Hospital type (Ref = general)
|
|
Specialized
|
0.2 (0.1, 0.2)
|
<0.001
|
|
Age at diagnosis (years) (Ref = ≥65)
|
|
<45
|
0.0 (−0.1, 0.1)
|
0.419
|
|
45–54
|
0.1 (0.0, 0.2)
|
0.131
|
|
55–64
|
0.0 (−0.1, 0.1)
|
0.522
|
|
Sex (Ref = women)
|
|
Men
|
0.0 (−0.1, 0.1)
|
0.969
|
|
Education (Ref = primary school or below)
|
|
Junior high school
|
0.0 (−0.1, 0.1)
|
0.815
|
|
Senior high school
|
0.0 (0.0, 0.1)
|
0.310
|
|
Undergraduate or higher
|
0.1 (0, 0.2)
|
0.134
|
|
Occupation (Ref = self-employee or unemployee)
|
|
Farmer
|
0.0 (−0.1, 0.2)
|
0.493
|
|
Enterprise or company employee/worker
|
−0.1 (−0.2, 0.0)
|
0.057
|
|
Retiree
|
0.1 (−0.1, 0.2)
|
0.377
|
|
Public sector employee
|
0.2 (0.1, 0.3)
|
0.004
|
|
Other
|
0.0 (−0.3, 0.2)
|
0.778
|
|
Healthcare insurance type (Ref = new rural cooperative medical scheme)
| | |
|
Urban employee basic medical insurance
|
0.0 (−0.1, 0.1)
|
0.641
|
|
Urban resident basic medical insurance
|
0.0 (−0.1, 0.1)
|
0.707
|
|
Commercial insurance
|
0.0 (−0.3, 0.4)
|
0.792
|
|
Self-paid
|
0.0 (−0.2, 0.2)
|
0.905
|
|
Other
|
0.4 (0.1, 0.7)
|
0.020
|
|
Previous-year household income (CNY) (Ref = ≤20,000)
|
|
20,000–39,999
|
0.1 (0.0, 0.2)
|
0.006
|
|
40,000–69,999
|
0.1 (0.0, 0.2)
|
0.046
|
|
≥70,000
|
0.1 (0.0, 0.2)
|
0.006
|
|
Clinical stage (Ref = I)
|
|
II
|
0.0 (−0.1, 0.1)
|
0.822
|
|
III
|
0.1 (0.0, 0.2)
|
0.099
|
|
IV
|
0.3 (0.1, 0.4)
|
<0.001
|
|
Pathologic type (Ref = others)
|
|
Adenocarcinoma
|
0.2 (0.1, 0.3)
|
<0.001
|
|
Therapeutic regimen (Ref = surgery)
|
|
Chemotherapy
|
0.2 (0.1, 0.3)
|
<0.001
|
|
Surgery and postoperative chemotherapy
|
0.2 (0.1, 0.3)
|
<0.001
|
|
Symptomatic treatment
|
0.1 (0.0, 0.2)
|
0.170
|
|
Concurrent chemoradiotherapy
|
0.8 (0.6, 1.0)
|
<0.001
|
|
Radiotherapy
|
0.5 (0.3, 0.7)
|
<0.001
|
|
Neoadjuvant chemotherapy and surgery
|
0.2 (−0.2, 0.6)
|
0.251
|
